A routine tuberculosis screening test may hold the key to identifying which adults face significantly elevated mortality risk within the next five years. The finding challenges the assumption that standard TB tests serve only infectious disease purposes, revealing they also capture fundamental immune system competence that correlates with survival.
Researchers analyzed interferon-gamma release assays (IGRAs) from 16,104 outpatients, focusing on how vigorously T-cells responded to mitogen stimulation—a measure of immune system activation capacity. Participants with the weakest T-cell responses (mitogen-nil values 0-1 IU/mL) showed 28% five-year mortality compared to 19% for those with robust responses (≥10 IU/mL). The mortality hazard ratios were striking: 2.77-fold higher at six months, 2.22-fold at one year, and 1.76-fold at five years for the low-response group.
This discovery addresses a critical gap in clinical practice: while immunosenescence is recognized as a hallmark of aging, few readily available laboratory tests directly measure immune function decline in ways that predict health outcomes. Most aging biomarkers focus on inflammation or cellular damage rather than functional immune capacity. The IGRA mitogen response essentially provides a real-time assessment of T-cell vigor—the immune system's ability to mount coordinated responses to threats.
The clinical implications are substantial since IGRAs are already performed routinely for TB screening in healthcare workers, transplant candidates, and high-risk populations. Healthcare systems could potentially repurpose existing test data to identify patients requiring more intensive monitoring or preventive interventions. However, this represents a single observational study requiring replication across diverse populations before clinical implementation.
